Incyte (INCY) Q1 2024 Earnings
Incyte reported Q1 2024 revenue of $880.9M, missed analyst consensus of $921.9M by $41.0M. Diluted EPS came in at $0.64, missed the $0.84 consensus by $0.20. Incyte reports across 3 business segments, led by Hematology, Oncology, and Inflammation and Autoimmunity (IAI).
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Incyte's Q1 2024 earnings report.
Incyte (INCY) reported Q1 2024 earnings on April 30, 2024 before market open.
Incyte reported revenue of $880.9M and diluted EPS of $0.64 for Q1 2024.
Revenue missed the consensus estimate of $921.9M by $41.0M. EPS missed the consensus estimate of $0.84 by $0.20.
You can read the 10-Q periodic report (0000879169-24-000077) directly on SEC EDGAR. The filing index links above go to sec.gov.